292 related articles for article (PubMed ID: 2436761)
1. Protective, tumor-selective dual pathway activation of 5-fluoro-2'-deoxycytidine provided by tetrahydrouridine in mice bearing mammary adenocarcinoma-755.
Boothman DA; Briggle TV; Greer S
Cancer Res; 1987 May; 47(9):2344-53. PubMed ID: 2436761
[TBL] [Abstract][Full Text] [Related]
2. Tumor-selective metabolism of 5-fluoro-2'-deoxycytidine coadministered with tetrahydrouridine compared to 5-fluorouracil in mice bearing Lewis lung carcinoma.
Boothman DA; Briggle TV; Greer S
Cancer Res; 1987 May; 47(9):2354-62. PubMed ID: 2952263
[TBL] [Abstract][Full Text] [Related]
3. Use of 5-fluorodeoxycytidine and tetrahydrouridine to exploit high levels of deoxycytidylate deaminase in tumors to achieve DNA- and target-directed therapies.
Mekras JA; Boothman DA; Perez LM; Greer S
Cancer Res; 1984 Jun; 44(6):2551-60. PubMed ID: 6539164
[TBL] [Abstract][Full Text] [Related]
4. Use of 5-trifluoromethyldeoxycytidine and tetrahydrouridine to circumvent catabolism and exploit high levels of cytidine deaminase in tumors to achieve DNA- and target-directed therapies.
Mekras JA; Boothman DA; Greer SB
Cancer Res; 1985 Nov; 45(11 Pt 1):5270-80. PubMed ID: 2932216
[TBL] [Abstract][Full Text] [Related]
5. Metabolic channeling of 5-fluoro-2'-deoxycytidine utilizing inhibitors of its deamination in cell culture.
Boothman DA; Briggle TV; Greer S
Mol Pharmacol; 1985 May; 27(5):584-94. PubMed ID: 2581125
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics, metabolism, and oral bioavailability of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine in mice.
Beumer JH; Eiseman JL; Parise RA; Joseph E; Holleran JL; Covey JM; Egorin MJ
Clin Cancer Res; 2006 Dec; 12(24):7483-91. PubMed ID: 17138702
[TBL] [Abstract][Full Text] [Related]
7. Incorporation of 5-fluorodeoxycytidine and metabolites into nucleic acids of human MCF-7 breast carcinoma cells.
Kaysen J; Spriggs D; Kufe D
Cancer Res; 1986 Sep; 46(9):4534-8. PubMed ID: 2425957
[TBL] [Abstract][Full Text] [Related]
8. Concentrations of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine (FdCyd) and its cytotoxic metabolites in plasma of patients treated with FdCyd and tetrahydrouridine (THU).
Beumer JH; Parise RA; Newman EM; Doroshow JH; Synold TW; Lenz HJ; Egorin MJ
Cancer Chemother Pharmacol; 2008 Jul; 62(2):363-8. PubMed ID: 17899082
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of potentiation of antitumor activity of 5-fluoro-2'-deoxyuridine in the adenocarcinoma 755 system by guanosine 5'-monophosphate.
Iigo M; Yamaizumi Z; Nakajima Y; Nishimura S; Hoshi A
Drugs Exp Clin Res; 1988; 14(4):257-63. PubMed ID: 2458897
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo radiation sensitization by the halogenated pyrimidine 5-chloro-2'-deoxycytidine.
Russell KJ; Rice GC; Brown JM
Cancer Res; 1986 Jun; 46(6):2883-7. PubMed ID: 3698014
[TBL] [Abstract][Full Text] [Related]
11. Metabolism and mechanism of action of 5-fluorodeoxycytidine.
Newman EM; Santi DV
Proc Natl Acad Sci U S A; 1982 Nov; 79(21):6419-23. PubMed ID: 6959127
[TBL] [Abstract][Full Text] [Related]
12. Combinations of tetrahydrouridine and cytosine arabinoside in mouse tumors.
Kreis W; Hession C; Soricelli A; Scully K
Cancer Treat Rep; 1977 Oct; 61(7):1355-64. PubMed ID: 589601
[TBL] [Abstract][Full Text] [Related]
13. The effect of inhibition of cytidine deaminase by tetrahydrouridine on the utilization of deoxycytidine and 5-bromodeoxycytidine for deoxyribonucleic acid synthesis.
Cooper GM; Greer S
Mol Pharmacol; 1973 Nov; 9(6):698-703. PubMed ID: 4762631
[No Abstract] [Full Text] [Related]
14. Radiation, pool size and incorporation studies in mice with 5-chloro-2'-deoxycytidine.
Santos O; Perez LM; Briggle TV; Boothman DA; Greer SB
Int J Radiat Oncol Biol Phys; 1990 Aug; 19(2):357-65. PubMed ID: 2394614
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of 5-[
Yu HM; Chiu CH; Chen WT; Wu CH; Lin PY; Huang YY; Chen JH; Tzen KY; Shiue CY; Lin WJ
Appl Radiat Isot; 2019 Jun; 148():152-159. PubMed ID: 30959352
[TBL] [Abstract][Full Text] [Related]
16. Stability of 5-fluoro-2'-deoxycytidine and tetrahydrouridine in combination.
Guo D; Myrdal PB; Karlage KL; O'Connell SP; Wissinger TJ; Tabibi SE; Yalkowsky SH
AAPS PharmSciTech; 2010 Mar; 11(1):247-52. PubMed ID: 20151336
[TBL] [Abstract][Full Text] [Related]
17. Biodistribution, Tumor Detection, and Radiation Dosimetry of
Young CR; Adler S; Eary JF; Lindenberg ML; Jacobs PM; Collins J; Kummar S; Kurdziel KA; Choyke PL; Mena E
J Nucl Med; 2019 Apr; 60(4):492-496. PubMed ID: 30389817
[TBL] [Abstract][Full Text] [Related]
18. Influence of tetrahydrouridine on the phosphorylation of 1-beta-D-arabinofuranosyl-cytosine (ara-C) by enzymes from solid tumors in vitro.
Furner RL; Mellett LB; Herren TC
J Pharmacol Exp Ther; 1975 Jul; 194(1):103-10. PubMed ID: 1057009
[TBL] [Abstract][Full Text] [Related]
19. Modulation of deoxycytidine metabolism in vivo with high-dose thymidine in mice.
Zaharko DS; Covey JM
J Natl Cancer Inst; 1983 Nov; 71(5):1033-9. PubMed ID: 6580479
[TBL] [Abstract][Full Text] [Related]
20. Kinetic alterations induced by 5-fluorouracil in bone marrow, intestinal mucosa, and tumor.
Myers CE; Young RC; Chabner BA
Cancer Res; 1976 May; 36(5):1653-8. PubMed ID: 1268826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
